NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Les is talking about the people who did not take any DCVax-L after progressing. I think Ex is correct that most people who did not crossover, likely could not crossover. Therefore, I think ex raises a good point not to consider the comparison of the 90% versus the 10% as very elucidating. My suggestion, with regard to that, is if you want to make a comparison to people who never received DCVax-L, you should compare the DCVax-L patients that did not "crossover" upon progression with the placebo's that did not crossover upon progression. That would be in keeping with a fair comparison.